Physiological conditions in the presence or absence of SL327 after MCA occlusion
| Treatment | CBF | HR | MABP | pCO2 | pO2 | pH |
|---|---|---|---|---|---|---|
| % | min−1 | mm Hg | mm Hg | mm Hg | ||
| DMSO | n = 12 | n = 6 | n = 6 | n = 6 | n = 6 | n = 6 |
| Before | 100 | 299 ± 38 | 84 ± 4 | 31 ± 2 | 190 ± 15 | 7.32 ± 0.04 |
| During | 18 ± 1 | 313 ± 24 | 74 ± 13 | 40 ± 3 | 198 ± 9 | 7.30 ± 0.04 |
| After | 86 ± 5 | 348 ± 40 | 87 ± 4 | 37 ± 1 | 204 ± 6 | 7.39 ± 0.02 |
| SL327 | n = 12 | n = 6 | n = 6 | n = 6 | n = 6 | n = 6 |
| Before | 100 | 296 ± 20 | 82 ± 5 | 32 ± 2 | 192 ± 16 | 7.33 ± 0.02 |
| During | 20 ± 1 | 291 ± 14 | 75 ± 7 | 45 ± 2 | 183 ± 27 | 7.31 ± 0.05 |
| After | 85 ± 4 | 315 ± 27 | 78 ± 7 | 37 ± 3 | 226 ± 13 | 7.28 ± 0.06 |
SL327 (100 mg/kg, i.p.) or vehicle (DMSO) was administered 15 min before MCAO. MCA was occluded for 30 min followed by reperfusion. The physiological data were measured before (prior to MCAO but after dosing), during (15 min after MCAO), or after (30 min of reperfusion) MCAO. CBF is shown as a percentage of the CBF level before MCAO. No statistical difference was observed in any of these groups treated with SL327 or vehicle.
HR, heart rate (per minute); MABP, mean arterial blood pressure (mm Hg).